OTSUKA PHARMACEUTICAL FACTORY, INC. Patent applications |
Patent application number | Title | Published |
20160120170 | TREHALOSE AND DEXTRAN-CONTAINING SOLUTION FOR TRANSPLANTING MAMMALIAN CELLS - The problem of the present invention is to provide a method for preserving mammalian cells over a long period of time using a solution for cell transplantation, capable of effectively suppressing cell death when the mammalian cells have been preserved, and the solution for cell transplantation. The present invention is characterized in that mammalian cells are preserved in a physiological aqueous solution for cell transplantation, comprising 2.0 to 6.0% (w/v) of trehalose, a derivative thereof, or a salt of trehalose or the derivative (a trehalose) and 4.0 to 7.0% (w/v) of dextran, a derivative thereof, or a salt of dextran or the derivative (a dextran). The effects of a trehalose and a dextran contained in the physiological aqueous solution for cell transplantation can suppress a decrease in the cell survival rate when mammalian cells are preserved for a long period of time (at least 14 days). | 05-05-2016 |
20160101231 | INFUSION PREPARATION - An object of the present invention is to provide an infusion preparation in which the Maillard reaction between an amino acid and a reducing sugar does not occur during storage and the size of fat particles in the fat emulsion does not increase during storage, and in which various types of vitamins can be incorporated in a stable manner, in spite of the fact that it is a two-chamber infusion preparation. Furthermore, even if only one of the infusions (of the infusion preparation) is administered, the patient is unlikely to develop hyperkalemia, vascular pain, or phlebitis. The present invention provides an infusion preparation containing two chambers separated by a partition that can be communicably opened, wherein a first chamber contains a first-chamber infusion containing a sugar and a fat emulsion, a second chamber contains a second-chamber infusion containing an amino acid and an electrolyte, the first-chamber infusion is substantially free of potassium, and has a relative osmotic pressure of 2.0 to 3.0, the second-chamber infusion has a potassium concentration of 40 mEq/L or less and a relative osmotic pressure of 2.5 to 3.5, and a mixture of the first- and second-chamber infusions has a potassium concentration of 16 mEq/L or more as measured upon communicably opening the partition. | 04-14-2016 |
20160095962 | ADHESION PREVENTING MATERIAL - An object of the present invention to provide an antiadhesive material designed to have time-varying fluidity as it exhibits a gel form of high fluidity at the time of administration, and exhibits a gel form of low fluidity after it is administered to an incised and sutured site. A powdery antiadhesive material to be mixed with an aqueous solvent upon use containing alginic acid and/or a salt thereof, that is configured to be mixed with the aqueous solvent upon use so that the viscosity at 37° C. is less than or equal to 70 mPas·s at the time of 5 minutes after mixing with the aqueous solvent, and the viscosity at 37° C. is more than or equal to 120 mPas·s at the time of 60 minutes after mixing, will have high fluidity at the time of administration when it is mixed with an aqueous solvent upon use in a clinical scene, and have low fluidity after it is administered to an incised and sutured site, and thus is capable of satisfying both the excellent operability and the antiadhesive effect. | 04-07-2016 |
20150290079 | DRUG CONTAINER STORAGE DEVICE, DRUG CONTAINER STORAGE SYSTEM, AND METHOD FOR SUCKING DRUG - There is provided a drug container storage device used for performing sucking of a drug contained in a drug container using a syringe, the syringe having a passage portion through which a liquid is sucked in and discharged, and the drug container having a lid portion that can be penetrated by the passage portion. The drug container storage device has a main body portion including a closed space configured to accommodate the drug container and a first opening; and an elastic sealing portion configured to hermetically seal the first opening of the main body portion and that can be penetrated by the passage portion of the syringe. The main body portion is configured to accommodate the drug container such that a space is formed between the lid portion of the accommodated drug container and the elastic sealing portion. | 10-15-2015 |
20150224145 | METHOD OF WASHING ADHERENT CELL USING TREHALOSE-CONTAINING CELL-WASHING SOLUTION - Methods of washing adherent cells, capable of effectively suppressing cell death due to proteolytic enzyme treatment for detaching the adherent cell from a culture vessel and subsequent cell treatment; cell-washing solutions used for the washing method; methods of producing cell suspensions for transplantation using the cell-washing solution; and kits comprising the cell-washing solution. Trehalose or its derivative or a salt thereof is added to physiological aqueous solutions to prepare cell-washing solutions containing trehalose or its derivative or a salt thereof as an active ingredient. The cell-washing solutions can be used to wash adherent cells before detaching the adherent cells from a culture vessel by proteolytic enzyme treatment to suppress cell death due to the proteolytic enzyme treatment. The concentration of trehalose applied to the cell-washing solution may be a concentration capable of suppressing the cell death due to the proteolytic enzyme treatment, such as 0.1 to 20 (w/v) %. | 08-13-2015 |
20150118196 | TREHALOSE-CONTAINING MAMMALIAN CELL SUSPENSION FOR PREVENTION OF PULMONARY EMBOLISM FORMATION - A mammalian cell suspension prevents pulmonary embolism formation during administration of mammalian cells, such as mammalian stem cells, through a blood vessel, and a preventive agent against pulmonary embolism formation during administration of mammalian cells through a blood vessel. suspending mammalian cells, such as mammalian stem cells, are suspended in a physiological aqueous solution containing trehalose or its derivative, or a salt thereof as an active ingredient to prepare a mammalian cell suspension for preventing pulmonary embolism formation during administration of the mammalian cells through a blood vessel, including the mammalian cells and trehalose or its derivative, or a salt thereof as active ingredients. Examples of the mammalian cells can include pancreatic islet cells, dendritic cells, natural killer cells, alpha/beta T cells, gamma/delta T cells, and cytotoxic T lymphocytes in addition to mammalian stem cells. Preferred mammalian stem cells can include mammalian mesenchymal stem cells and mammalian pluripotent stem cells. | 04-30-2015 |
20150045453 | EMULSIFIED FOOD PRODUCT COMPOSITION - The purpose of the present invention is to provide an emulsified food product composition having good fluidity and emulsification stability, even when subjected to heat sterilization treatment, with which gastro-esophageal reflux can be prevented by gelling upon entering the stomach. By adding a gelling agent for gelling in the acidic region, at least one emulsion stabilizer selected from the group consisting of gum arabic and gum ghatti, and a divalent metal salt to the emulsified food product composition comprising a lipid, it is possible to realize the property of gelling upon entering the stomach and obtain good fluidity and emulsification stability, even if a heat sterilization treatment is used. | 02-12-2015 |
20140093961 | METHOD OF WASHING ADHERENT CELL USING TREHALOSE-CONTAINING CELL-WASHING SOLUTION - Methods of washing adherent cells, capable of effectively suppressing cell death due to proteolytic enzyme treatment for detaching the adherent cell from a culture vessel and subsequent cell treatment; cell-washing solutions used for the washing method; methods of producing cell suspensions for transplantation using the cell-washing solution; and kits comprising the cell-washing solution. Trehalose or its derivative or a salt thereof is added to physiological aqueous solutions to prepare cell-washing solutions containing trehalose or its derivative or a salt thereof as an active ingredient. The cell-washing solutions can be used to wash adherent cells before detaching the adherent cells from a culture vessel by proteolytic enzyme treatment to suppress cell death due to the proteolytic enzyme treatment. The concentration of trehalose applied to the cell-washing solution may be a concentration capable of suppressing the cell death due to the proteolytic enzyme treatment, such as 0.1 to 20 (w/v)%. | 04-03-2014 |
20140073051 | METHOD FOR PRODUCING SHEET-LIKE PANCREATIC ISLET - The present invention provides a method of producing a sheet-like pancreatic islet, comprising culturing an isolated pancreatic islet in a culture vessel, wherein a polypeptide comprising an EC1 domain of E-cadherin and having a binding ability to said E-cadherin is fixed on or applied to a surface of a solid phase, while being adhered to the solid phase surface for a period sufficient for the pancreatic islet to take a sheet-like form. | 03-13-2014 |
20130313261 | INFUSION PREPARATION - An object of the present invention is to provide an infusion preparation in which the Maillard reaction between an amino acid and a reducing sugar does not occur during storage and the size of fat particles in the fat emulsion does not increase during storage, and in which various types of vitamins can be incorporated in a stable manner, in spite of the fact that it is a two-chamber infusion preparation. Furthermore, even if only one of the infusions (of the infusion preparation) is administered, the patient is unlikely to develop hyperkalemia, vascular pain, or phlebitis. The present invention provides an infusion preparation containing two chambers separated by a partition that can be communicably opened, wherein a first chamber contains a first-chamber infusion containing a sugar and a fat emulsion, a second chamber contains a second-chamber infusion containing an amino acid and an electrolyte, the first-chamber infusion is substantially free of potassium, and has a relative osmotic pressure of 2.0 to 3.0, the second-chamber infusion has a potassium concentration of 40 mEq/L or less and a relative osmotic pressure of 2.5 to 3.5, and a mixture of the first- and second-chamber infusions has a potassium concentration of 16 mEq/L or more as measured upon communicably opening the partition. | 11-28-2013 |
20130296342 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES - The present invention provides pharmaceutical compositions containing benzene compound(s) represented by General Formula (1) below and, particularly, LPL-activating compositions for use in hyperlipidemia therapeutic and preventive agents, anti-obesity agents, and the like: | 11-07-2013 |
20130260461 | STEM CELL SUSPENSION - The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like. | 10-03-2013 |
20130177986 | PANCREATIC ISLET SEPARATION METHOD, AND PROTECTIVE SOLUTION FOR PROTECTING PANCREATIC ISLET TISSUE - The disclosed islet isolation method comprises: an injection step of injecting a preservation solution into the pancreatic duct of an excised pancreas; a preservation step of immersing the pancreas into an immersion fluid for preservation; a digestion step of breaking down the pancreas to provide pancreatic tissue; and a purification step of immersing the pancreatic tissue in a purification solution to provide islets. The digestion step consists of: an enzyme injection step of injecting an enzyme solution containing a digestion enzyme into the pancreas; a digestion initiation step of activating the digestion enzyme; a digestion termination step of inactivating the digestion enzyme; and a collection step of collecting the broken-down pancreatic tissue. The islet isolation method is characterized in that, by adding a neutrophil elastase inhibitor to the system before the digestion initiation step, the neutrophil elastase inhibitor is present inside the pancreas at the time point of starting the digestion initiation step. By using the above method and a protective solution which can be used in the method, islets having a size and shape suitable for transplantation can be obtained in high yields. | 07-11-2013 |
20130071587 | MULTILAYER FILM AND BAG FORMED OF MULTILAYER FILM - A multilayer film comprising an upper layer (A), at least one intermediate layer (B), and a lower layer (C) stacked in that order, | 03-21-2013 |
20130059913 | COMPOSITION FOR AMELIORATION OF HYPOALBUMINEMIA - The present invention is directed to a composition for ameliorating hypoalbuminemia containing a branched-chain amino acid(s) as an active ingredient(s), wherein the composition contains leucine and/or isoleucine as the active ingredient(s) and does not contain valine. As the above branched-chain amino acid(s), leucine and isoleucine are preferably contained. The mass ratio of leucine to isoleucine described above is preferably from 0.1 to 10. As the above branched-chain amino acid(s), either leucine or isoleucine alone may be contained. The present invention is suitably used as an infusion formulation, an oral formulation or a food or drink. | 03-07-2013 |
20110275823 | PHENYLIMIDAZOLE COMPOUNDS - [Object] To provide a pharmaceutical product (chemotherapeutic agent) effective in the prevention and treatment of hyperlipidemia, obesity, etc. | 11-10-2011 |
20110262959 | METHOD FOR EVALUATION OF DIFFERENTIATION ABILITY OF STEM CELL - The present invention provides a method of evaluating the possibility of a stem cell being able to differentiate into a cell that constitutes a desired tissue in a living organism, comprising the following steps of:
| 10-27-2011 |
20110166089 | SOLUTION FOR TISSUE ADHESION PREVENTION AND METHOD FOR TISSUE ADHESION PREVENTION - The objective of the invention is to provide a solution for tissue adhesion prevention and a method for tissue adhesion prevention that are applicable to general surgery and in which covering condition during surgery is stable and convenient. The invention is the solution for tissue adhesion prevention of which the active ingredient is trehalose. Also, it contains at least one or more among antioxidants, chelates, antiseptics, hemostatics, anti-inflammatory agents, and polysaccharides, mucopolysaccharides, salts of polysaccharides and salts of mucopolysaccharides having lubricating properties. This solution for tissue adhesion prevention is provided as any form of perfusion fluid, spray fluid, solution for spray or vaporization administration, foam-like aerosol preparation, injection solution for intravenous fluids, intravenous fluid. | 07-07-2011 |
20110104656 | ARTIFICIAL KIDNEY PRECURSOR AND PROCESS FOR PRODUCTION THEREOF - The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production thereof. | 05-05-2011 |
20110065728 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES - The present invention provides pharmaceutical compositions containing benzene compound(s) represented by General Formula (1) below and, particularly, LPL-activating compositions for use in hyperlipidemia therapeutic and preventive agents, anti-obesity agents, and the like: | 03-17-2011 |
20100331423 | AQUEOUS SOLUTION OF OLANEXIDINE, METHOD OF PREPARING THE AQUEOUS SOLUTION, AND DISINFECTANT - The present invention provides a disinfectant that contains olanexidine in a concentration sufficient to exhibit an effective bactericidal effect, and that has hardly any side effects such as skin irritation. Specifically, the present invention provides a disinfectant containing an aqueous solution that contains olanexidine and at least an equimolar amount of gluconic acid, and substantially contains neither an acid other than gluconic acid nor a salt of the acid other than gluconic acid. | 12-30-2010 |
20100330197 | ORAL OR ENTERAL COMPOSITION USEFUL FOR RECOVERY OF PHYSICAL FUNCTIONS - The present invention provides an oral or enteral composition incorporating not only BCAA but other nutrients to be conducive to comprehensive recovery from fatigue, and improvement in total physical condition. | 12-30-2010 |
20100324280 | SODIUM ABSORPTION INHIBITOR, POTASSIUM ABSORPTION INHIBITOR, PHOSPHORUS ABSORPTION INHIBITOR AND PREVENTIVE AGENT, THERAPEUTIC AGENT AND FOOD CONTAINING THE SAME - The present invention provides a sodium absorption inhibitor, a potassium absorption inhibitor, and a phosphorus absorption inhibitor, and a preventive agent, a therapeutic agent and a food for diseases caused by overconsumption of common salt, potassium and phosphorus or diseases which require restriction of ingestion of common salt, potassium and phosphorus to actively and safely excrete overconsumed common salt, potassium and phosphorus excreted outside the body. | 12-23-2010 |
20100323975 | THERAPEUTIC AGENT FOR CEREBRAL ISCHEMIC INJURY - A therapeutic agent for cerebral ischemic injury contains at least one selected from L-alanyl-L-histidine and glycyl-L-histidine as an active ingredient. The therapeutic agent for cerebral ischemic injury preferably has a dosage form as an injection for intravenous administration. The therapeutic agent for cerebral ischemic injury having a dosage form as an aqueous injection contains at least one selected from L-alanyl-L-histidine and glycyl-L-histidine at a concentration of preferably 0.3 to 3.5 mol/L, and more preferably 0.6 to 2.1 mol/L. | 12-23-2010 |
20100228099 | DEVICE FOR PREDICTING PROGNOSIS OF PATIENTS WHO UNDERGO PEG OPERATION, METHOD FOR PREDICTING PROGNOSIS OF PATIENTS WHO UNDERGO PEG OPERATION AND COMPUTER READABLE MEDIUM - The present invention provides a device for predicting prognosis of a patient who undergoes PEG, which allows a doctor to obtain predictive results sufficient to judge whether or not to perform the PEG (percutaneous endoscopic gastrostomy) for the patient. This device includes: a prognosis prediction expression storage section | 09-09-2010 |
20100224508 | Ink composition for sensing carbon dioxide gas, carbon dioxide indicator using the same, package provided with the carbon dioxide indicator, and method for sensing pinhole using the same - An ink composition for sensing carbon dioxide gas contains a pH indicator formed using a combination of two or more types of pH indicator components, binder, and solvent and allows easy visual observation of color changes of an indicating portion caused by the concentration of carbon dioxide gas. When the ink composition is applied to a carbon dioxide indicator and package, a pinhole and poor seal of a carbon-dioxide-ambient package are easily found. | 09-09-2010 |
20100178363 | AGENT FOR PREVENTING BLEEDING FROM CEREBRAL CORTICAL VEIN - The present invention provides: a superficial cerebral vascular bleeding inhibitor comprising an aqueous solution containing 120 to 160 mEq/L of sodium ion, 1 to 5 mEq/L of calcium ion, and 75 to 165 mEq/L of chloride ion; the superficial cerebral vascular bleeding inhibitor further comprising 1 to 5 mEq/L of potassium ion; and a packaged container containing the superficial cerebral vascular bleeding inhibitor (with or without potassium ion). The superficial cerebral vascular bleeding inhibitor of the present invention can effectively prevent or inhibit bleeding from superficial cerebral blood vessels in the field of neurosurgery such as intracranial surgery and the like, thereby capable of securing a clear operating field during intracranial surgery and inhibiting the occurrence of post-surgery damage. | 07-15-2010 |
20100105774 | ANTIDEPRESSANT - An antidepressant containing, as an active ingredient, at least one compound selected from a branched amino acid, a pharmaceutically acceptable salt thereof and a derivative thereof. | 04-29-2010 |
20100028883 | METHOD FOR EVALUATION OF TISSUE PRESERVATION SOLUTION - The present invention provides a method for evaluating preservative effect of a tissue preservation solution, comprising immersing a mammalian tissue introduced with a luminescence or fluorescence labeling gene in the tissue preservation solution, measuring a luminescence or fluorescence level by the labeling gene in the tissue after immersion, and evaluating the preservative effect of the tissue preservation solution based on the luminescence or fluorescence level. | 02-04-2010 |
20090131903 | Cover for Being Mounted on a Multi-Compartment Infusion Bag - An object of the present device is to provide a cover capable of preventing the administration of unmixed medicaments to a patient. | 05-21-2009 |
20090069445 | PROPOFOL-CONTAINING FAT EMULSIONS - This invention provides a propofol-containing fat emulsion preparation including: 0.1 to 2 w/v % of propofol, 10 to 20 w/v % of an oily component, and 2 to 5 w/v % of an emulsifier, the weight of the oily component being in the range of about 5 to about 200 times the weight of propofol, the weight of the emulsifier being in the range of about 0.9 to about 50 times that of propofol, and the average size of emulsion particles being 180 nm or less, and a method for preparing the same. Propofol-containing fat emulsion preparation of this invention alleviates the vascular pain that occurs during the administration thereof without incorporating a local anesthetic, such as lidocaine or the like, therein. | 03-12-2009 |
20080215016 | Medical Tubes - Medical tubes are well balanced in transparency, flexibility, heat resistance, scratch resistance and rubber elasticity. | 09-04-2008 |